ClinicalTrials.gg
CompletedNCT02445352ROSEUpdated May 15, 2015

Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia

A Phase 3 interventional study of Rosuvastatin 5mg and DP-R207 5/10mg in Primary Hypercholesterolemia, sponsored by Alvogen Korea. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2015-05-15.

Sponsored by Alvogen Korea (part of Lotus Pharmaceutical Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
379
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Enrollment
24th of 57
379 · median 203
Started
2014
with 2 others
Phase 3
33 of 59
none open now
Registered
44th of 59
by date
Lead sponsor
1 of 59
Alvogen Korea

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 24th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2014, is one of 33 in phase 3, and was the 44th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of DP-R207 in patients with primary hypercholesterolemia.

03

Conditions studied

  • Primary Hypercholesterolemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged over 19 years
  • Signed form
  • At visit 1 and visit 2, LDL-Cholesterol ≤ 250mg/dL and Triglyderide ≤ 350mg/dL

Exclusion criteria

Exclusion Criteria:

  • Has a history of to HMG-CoA reductase inhibitor and component of ezeimibe
  • Liver transaminases > 2 x
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
379 participants (actual)

Study arms

  • Active comparator
    Rosuvastatin 5mg & Placebo & Placebo

    Once a day, administration of rosuvastatin 5mg and two types of placebo for 20 weeks

    Drug: Rosuvastatin 5mg · Drug: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg) · Drug: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)

  • Experimental
    DP-R207 5/10mg & Placebo & Placebo

    Once a day, administration of DP-R207 5/10mg and two types of placebo for 20 weeks

    Drug: DP-R207 5/10mg · Drug: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg) · Drug: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)

  • Active comparator
    Rosuvastatin 10mg & Placebo & Placebo

    Once a day, administration of rosuvastatin 10mg and two types of placebo for 20 weeks

    Drug: Rosuvastatin 10mg · Drug: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg) · Drug: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)

  • Experimental
    DP-R207 10/10mg & Placebo & Placebo

    Once a day, administration of DP-R207 10/10mg and two types of placebo for 20 weeks

    Drug: DP-R207 10/10mg · Drug: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg) · Drug: Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)

  • Active comparator
    Rosuvastatin 20mg & Placebo & Placebo

    Once a day, administration of rosuvastatin 20mg and two types of placebo for 20 weeks

    Drug: Rosuvastatin 20mg · Drug: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg) · Drug: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)

  • Experimental
    DP-R207 20/10mg & Placebo & Placebo

    Once a day, administration of DP-R207 20/10mg and two types of placebo for 20 weeks

    Drug: DP-R207 20/10mg · Drug: Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg) · Drug: Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)

Interventions

  • DrugDP-R207 5/10mg

    Drug page: Rosuvastatin

    Also known as: Rosuvastatin 5mg, Ezetimibe 10mg

  • DrugDP-R207 10/10mg

    Drug page: Rosuvastatin

    Also known as: Rosuvastatin 10mg, Ezetimibe 10mg

  • DrugDP-R207 20/10mg

    Drug page: Rosuvastatin

    Also known as: Rosuvastatin 20mg, Ezetimibe 10mg

  • DrugPlacebo (for Rosuvastatin 5mg and DP-R207 5/10mg)
  • DrugPlacebo (for Rosuvastatin 10mg and DP-R207 10/10mg)
  • DrugPlacebo (for Rosuvastatin 20mg and DP-R207 20/10mg)
06

What researchers measure

Primary outcomes

  1. Percent change from baseline to 8 weeks in LDL-Cholesterol

    Time frame: baseline and 8 weeks

Secondary outcomes

  1. Percent change from baseline to 4 weeks in LDL-Cholesterol

    Time frame: baseline and 4 weeks

  2. Percent change from baseline to 4 weeks in lipid related blood test results

    Time frame: baseline and 4 weeks

  3. Percent change from baseline to 8 weeks in lipid related blood test results

    Time frame: baseline and 8 weeks

  4. Percentage of patients reaching treatment goals according to NCEP ATP III Guideline

    Time frame: week 4 and week 8

07

Study locations

1 site
  • Severance Hospital
    Seodaemun-gu, Seoul 120-752, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Jan 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2015
First posted
May 15, 2015
Start
Jul 2014
Primary completionActual
Jan 2015
CompletionActual
Mar 2015
Last update
May 15, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02445352
Lead sponsor
Alvogen Korea
Responsible party
Sponsor
First posted
May 15, 2015
Start date
Jul 2014
Primary completion
Jan 2015
Completion
Mar 2015
Last update
May 15, 2015

Study contacts

Yangsoo Jang, Ph.D.
study chair · Severance Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion